Enoxaparin in ACS

More documents

Recommendations

Info

Primary End Point (ITT)Death/MI at 1 Year18 UFH17.0%Point (%%)Primaary End1614121012.0%9.9%8 RR0.836 (0.77to 0.90)P
Net Clinical BenefitDeath/MI/Disabling Stroke at 1 yrEnd Pooint (%)181614 12.3%1210 10.1%8 RR0.826 (0.76to 0.89)4 P
Page 1 and 2: Enoxaparin in ACSWhen evidence meet
Page 3 and 4: o DefinitionsAgendao Is UFH w/o dis
Page 5 and 6: Superiority ofEnoxaparin over UFHEv
Page 7 and 8: Coronary patency (TIMI flow 2 or 3)
Page 9 and 10: Enoxaparin versus UFH for STEMIOne
Page 11 and 12: No Increase in ICHents% Ev10UFHENOX
Page 13: New Data from ExTRACT-TIMI 251YEAR
Page 17 and 18: Summary-23. Net clinical benefit si
Page 19 and 20: Enoxaparin and GP IIb/IIIa inhibito
Page 21 and 22: NICE -3Objectiveso To assess the sa
Page 23 and 24: o DefinitionsAgendao Is UFH w/o dis
Page 25 and 26: Clexane in ACS - My ApproachACSCons
Page 27: Egyptian Guidelines for themanageme

Enoxaparin in ACS

Create successful ePaper yourself

Delete template?

Save as template?